Ignite Creation Date:
2025-12-24 @ 2:19 PM
Ignite Modification Date:
2025-12-25 @ 2:06 PM
Study NCT ID:
NCT00378495
Status:
TERMINATED
Last Update Posted:
2016-07-12
First Post:
2006-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Miltefosine for Brazilian Visceral Leishmaniasis
Sponsor:
AB Foundation
Organization:
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
accrual criteria being reviewed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Miltefosine will be administered to Brazilian patients with kala azar
Detailed Description:
Miltefosine will be administered to Brazilian patients with kala azar. Both pediatric and adult patients will be studied. Patients will be followed for 6 months.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: